The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer: Kanagawa Breast Oncology Croup (KBOG) 1101 study.
Takashi Ishikawa
No relevant relationships to disclose
Daisuke Shimizu
No relevant relationships to disclose
Mikiko Tanabe
No relevant relationships to disclose
Mari S.Oba
No relevant relationships to disclose
Takeshi Sasaki
No relevant relationships to disclose
Satoshi Morita
No relevant relationships to disclose
Kumiko Kida
No relevant relationships to disclose
Shuichi Nawata
No relevant relationships to disclose
Masatoshi Mogaki
No relevant relationships to disclose
Takako Doi
No relevant relationships to disclose
Koichiro Tsugawa
No relevant relationships to disclose
Haruki Ogata
No relevant relationships to disclose
Yoshimasa Kosaka
No relevant relationships to disclose
Norihiko Sengoku
No relevant relationships to disclose
Yasuhiro Suzuki
No relevant relationships to disclose
Akihiko Suto
No relevant relationships to disclose
Takashi Chishima
No relevant relationships to disclose
Yasushi Ichikawa
No relevant relationships to disclose
Itaru Endo
No relevant relationships to disclose
Yutaka Tokuda
No relevant relationships to disclose